JP Morgan upgrades Pinterest on engagement gains, attractive valuation
Investing.com -- JP Morgan upgraded Pinterest Inc (NYSE:PINS) to Overweight from Neutral and raised its price target to $40 from $35, citing improved user engagement, monetization gains, and an undemanding valuation.
Pinterest has a growing user base, improving ad revenue, and expanding profit margins. Despite a 10% year-to-date gain, PINS shares are still down 18% from February highs, presenting what JP Morgan sees as a favorable entry point.
JP Morgan noted that 85% of users access Pinterest via its mobile app, which also drives over 90% of the company's revenue, reducing exposure to broader search platform volatility. Analysts believe Pinterest's full-funnel ad platform and AI tools like Performance+ are helping capture a larger share of ad budgets, especially from mid-sized advertisers.
The firm expects 14% revenue growth in both Q2 and full-year 2025, and sees room for further upside. Pinterest is also nearing the low end of its targeted 30-34% adjusted EBITDA margin range, and JPMorgan believes faster top-line growth and cost control could drive multi-year margin expansion.
At 13x 2026 free cash flow and 12x 2026 adjusted EBITDA, the stock trades below historical averages, while stock-based compensation as a percentage of EBITDA is expected to decline. The new $40 price target reflects a 15.5x multiple on 2026 estimated EBITDA of $1.54 billion.
JP Morgan sees solid execution and underappreciated fundamentals as reasons for a more bullish stance, calling Pinterest's risk/reward 'favorable.'
Related articles
JP Morgan upgrades Pinterest on engagement gains, attractive valuation
Goldman Sachs starts coverage on auto services stock with mixed ratings
Truist upgrades Oshkosh saying stock 'too cheap to ignore'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
CCTV Script 06/06/25
The war of words between Elon Musk and Donald Trump, which seemed to escalate almost hourly, has already cost real money in the capital markets. Overnight, Musk's personal net worth reportedly fell by approximately $34 billion. By aligning the timing of their social media exchanges with Tesla's stock movements, a clear pattern emerges: as the feud grew more intense, with language becoming increasingly blunt and emotional, Tesla's share price continued to slide. Many analysts believe that Tesla's stock is likely to remain volatile. To assess its future trajectory, we can start with the trigger of this conflict: a recently passed House spending bill. One provision would eliminate tax credits for electric vehicles—directly impacting Tesla. JPMorgan analysts estimate that the new legislation could cut Tesla's annual profits by around $1.2 billion. However, some market observers note that both Musk and others in the industry had long anticipated that the Trump administration would eventually scrap EV subsidies. This expectation has been priced in—it was only a matter of timing. But of even greater consequence is the second layer of impact: the broader regulatory posture of the White House toward Musk, particularly in the autonomous driving space. Timing is critical. Next week, Tesla is expected to debut its long-awaited Robotaxi service in Austin, Texas. Progress in self-driving technology has been a key reason many investors remain bullish on Tesla. But the breakdown in Musk's relationship with Trump could undermine those expectations. "there's a view that the battle here going on between musk and Trump, that this is going to continue to sort of, you know, increase, and with that, ultimately does is that autonomous and the regulatory vision does Trump now, now not start to play nice in the sandbox with musk.""Elon Musk, as brilliant as he can be, can also be mercurial and impetuous. CUT TO from a trading perspective, I think the stock could easily trade down into the 250s 260s until you get some support." Beyond the personal feud, the spotlight is also shifting to the broader relationship between Silicon Valley—the U.S. tech hub—and Washington, D.C.—the political center. As Musk and Trump move from allies to adversaries, their split is drawing attention to the evolving dynamic between big tech and federal power. Analysts told CNBC that during Trump's first term, major tech firms often found themselves in the administration's crosshairs. Companies like Meta, Google, and to some extent Apple were all named in antitrust inquiries. Now, the rift between Musk and Trump may open new doors for tech leaders who have had tense relations with Musk. For instance, Jeff Bezos—who also leads a space company—has in recent months made efforts to court Trump more closely, reportedly taking cues from Musk's political playbook. This shift may also present an opportunity for Sam Altman, CEO of AI startup OpenAI. "If you're a startup that's trying to make big names or big headlines with investments for the US, that's probably a good place to be." Still, some analysts caution that this overnight drama may not deserve too much attention. A defining feature of the Trump-era policymaking process has always been its volatility—things can shift dramatically within just a few hours. What ultimately matters is returning to the fundamentals and taking a long-term view of where the industry—and the economy—are heading.
Yahoo
2 hours ago
- Yahoo
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth customers. Shares have soared, but still have a ton of potential for patient long-term shareholders. 10 stocks we like better than Hims & Hers Health › Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
1 Top Dow Dividend Stock to Buy for Passive Income in June
Verizon has a dividend yield of more than 6%, triple the average Dow stock. The telecom company produces lots of cash to cover its dividend and invest in growing its business. It has a strong balance sheet, giving it ample financial flexibility to fund its dividend and growth. 10 stocks we like better than Verizon Communications › The Dow Jones Industrial Average tracks 30 large, publicly traded blue chip stocks. These companies are some of the strongest and most well-known in the country. They tend to be lower-risk companies, most of which pay dividends. Because of that, Dow stocks can be a great choice for those seeking reliable dividend income. Of the 30 Dow stocks, Verizon (NYSE: VZ) stands out for its high dividend yield. At over 6%, it's more than triple the average dividend yield of Dow stocks (less than 2%). That makes the telecom giant an ideal dividend stock to buy for passive income this month. A high dividend yield can sometimes suggest that a company has a higher risk profile. However, that's not the case with Verizon. The telecom giant produces prodigious cash flows and boasts a rock-solid financial profile. Last year, Verizon generated $36.9 billion in cash flow from operations. It invested $17.1 billion into capital projects to maintain and expand its 5G and fiber networks. That left Verizon with $19.8 billion in free cash flow, which easily covered the company's $11.2 billion in dividend payments to shareholders. The remaining excess free cash flow enabled the telecom giant to strengthen its already solid balance sheet. Its leverage ratio fell from 2.6 times at the end of 2023 to 2.3 times at the end of last year. That's a solid leverage ratio for a company that generates stable cash flow. It backs the company's strong A-/BBB+/Baa1 bond ratings. Verizon's long-term goal is to have an even lower leverage ratio in the range of 1.75x to 2.0x, putting it on an even stronger financial foundation. Verizon's robust cash flows and strong financial profile have enabled the company to steadily increase its dividend. Last September, the company delivered its 18th consecutive annual dividend increase, raising its payment by around 2%. That's the longest current streak in the U.S. telecom sector. The company should be able to continue increasing its dividend in the future. It's investing heavily in 5G and fiber to provide faster wireless and broadband services to customers. That strategy is driving the company's financial growth this year. Its wireless services revenue rose 2.7% in the first quarter to an industry-leading $20.8 billion. Meanwhile, its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 4% to $12.6 billion, the highest in the company's history. Verizon also produced $3.6 billion in free cash flow after capital expenses in the first quarter, a 34% jump compared to the year-ago period. Verizon has budgeted between $17.5 billion and $18.5 billion for capital expenditures this year to maintain and expand its network. That will leave it with $17.5 billion to $18.5 billion in free cash flow, more than enough to cover its dividend and continue strengthening its balance sheet. The company is using some of its financial flexibility to acquire Frontier Communications in a $20 billion all-cash deal that it hopes to close early next year. The acquisition will significantly expand its fiber network while generating at least $500 million in annual cost savings. Verizon will use its growing excess free cash flow to repay the debt it will take on to close that deal. It should return to its current level within two years of closing the acquisition. That would free up additional cash that Verizon could use to repurchase stock. The growing free cash flow from its capital investments and the Frontier deal should enable Verizon to continue to steadily increase its high-yielding dividend. Verizon is a rare high-yielding blue chip dividend stock. It provides investors with a bond-like income stream with some upside potential from a rising dividend and the possibility of an increasing stock price. These features make it an ideal option for those seeking a bankable income stream backed by a top Dow stock. Before you buy stock in Verizon Communications, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Verizon Communications wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Matt DiLallo has positions in Verizon Communications. The Motley Fool recommends Verizon Communications. The Motley Fool has a disclosure policy. 1 Top Dow Dividend Stock to Buy for Passive Income in June was originally published by The Motley Fool Sign in to access your portfolio
